New Imported Drug Approvals by the NMPA - October 2024 | China Medical News

November: New Imported Drug Approvals by the NMPA - October 2024

□　Niraparib Tosylate and Abiraterone Acetate Tablets (Brand; N/A) – marketed by Janssen-Cilag International NV
□　Pirtobrutinib Tablets (Brand; Jaypirca) – marketed by Eli Lilly Nederland B.V.
□　Faricimab Injection (Brand; VABYSMO) – new indication for macular edema secondary to CRVO or BRVO – marketed by Roche Pharma (Schweiz) AG
□　Trastuzumab Deruxtecan for Injection (Brand; You He De) – new indication for unresectable or metastatic NSCLC with HER2 mutations – marketed by Daiichi Sankyo Europe GmbH

(Source: BaiPharm)